Colorado HB 19-1131 Disclosure

Qelbree® (Viloxazine)

Supernus Pharmaceuticals, Inc. (Supernus) provides the following information to Colorado prescribers, as required by Colorado House Bill 19-1131.

The pricing information below reflects Supernus Wholesale Acquisition Costs ("WAC") for the Supernus Pharmaceuticals, Inc. product: Qelbree®. The WAC represents published catalogue or list price and may not represent actual transactional prices.

The price a customer pays may vary from the prices listed, depending, for example, on how the customer purchases the product, the availability of discounts, the wholesaler/distributor, or other charges.

WAC for Qelbree®

PRODUCT	NDC	DOSAGE FORM AND STRENGTH	WHOLESALE ACQUISITION COST (WAC)
Qelbree® (Viloxazine)	17772-0131-30	Capsule 100 MG	$400.14
Qelbree® (Viloxazine)	17772-0132-30	Capsule 150 MG	$400.14
Qelbree® (Viloxazine)	17772-0133-30	Capsule 200 MG	$400.14
Qelbree® (Viloxazine)	17772-0133-60	Capsule 200 MG	$800.28

The list below provides the names of generic prescription drugs in the same Therapeutic Class as the Qelbree®. Note that the drugs listed are not necessarily the generic form of the Qelbree®. Rather, these drugs could be the generic form of a drug in the same Therapeutic Class.

This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product's FDA-approved label and indication for further information.

Generic Prescription Drugs in the Same Therapeutic Class*
DRUG #1 Atomoxetine HCl
DRUG #2 Methylphenidate
DRUG #3 Dexmethylphenidate

* Source: Generic Prescription Drug Data Extracted from Medi-Span

For purposes of listing the generic prescription drugs above, the Therapeutic Class is derived from Medi-Span

Qelbree® is a registered trademark of Supernus Pharmaceuticals, Inc.
Copyright© 2026 Supernus All rights reserved.
10/15/2026